摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(benzothiazol-2-ylthio)-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]hexanamide | 835612-96-9

中文名称
——
中文别名
——
英文名称
6-(benzothiazol-2-ylthio)-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]hexanamide
英文别名
6-(benzothiazol-2-ylthio)-N-[2,4-bis(methylthio)-6-methyl-pyridin-3-yl]hexanamide;6-(1,3-benzothiazol-2-ylsulfanyl)-N-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]hexanamide
6-(benzothiazol-2-ylthio)-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]hexanamide化学式
CAS
835612-96-9
化学式
C21H25N3OS4
mdl
——
分子量
463.713
InChiKey
ANJQSFDYMRHPPB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    29
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    159
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • Novel amide compounds and medications containing the same
    申请人:Shibuya Kimiyuki
    公开号:US20050131002A1
    公开(公告)日:2005-06-16
    The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group, Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring, X represents —NH—, an oxygen atom or a sulfur atom, Y represents —NR 4 —, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone, Z represents a single bond or —NR 5 —, R 4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, R 5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, and n is an integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at least one of these compounds.
    本发明提供了一种具有ACAT抑制活性的新化合物。本发明涉及由式(I)表示的化合物,其中表示一种可选取代的二价残基,例如苯,吡啶,环己烷或萘,或者一个基团,Het表示一种5-至8-成员的取代或未取代的杂环基团,其中至少包含从氮原子,氧原子和硫原子中选取的一种杂原子,例如单环基团,多环基团或融合环的基团,X表示-NH-,氧原子或硫原子,Y表示-NR4-,氧原子,硫原子,亚砜或磺酰基,Z表示单键或-NR5-,R4表示氢原子,低碳基,芳基或可选取代的硅烷低碳基,R5表示氢原子,低碳基,芳基或可选取代的硅烷低碳基,n为1到15的整数,或其盐或溶剂,以及含有这些化合物中至少一种的药物组合物。
  • Novel amide compounds and medications containing the same technical field
    申请人:Shibuya Kimiyuki
    公开号:US20050131001A1
    公开(公告)日:2005-06-16
    The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group, Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring, X represents —NH—, an oxygen atom or a sulfur atom, Y represents —NR 4 —, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone, Z represents a single bond or —NR 5 —, R 4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, R 5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, and n is an integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at least one of these compounds.
    本发明提供了一种具有ACAT抑制活性的新化合物。本发明涉及由式(I)表示的化合物,其中表示可选取代的二价残基,例如苯,吡啶,环己烷或萘,或基团,Het表示包含至少一种异原子(从氮原子,氧原子和硫原子中选择)的5-至8-成员取代或未取代的杂环基团,例如单环基团,多环基团或融合环基团,X表示-NH-,氧原子或硫原子,Y表示-NR4-,氧原子,硫原子,亚砜或磺酰基,Z表示单键或-NR5-,R4表示氢原子,低碳基,芳基或可选取代的硅基低碳基,R5表示氢原子,低碳基,芳基或可选取代的硅基低碳基,n为1至15的整数,或其盐或溶剂,以及含有这些化合物中至少一种的药物组合物。
  • NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME
    申请人:Kowa Company Ltd.
    公开号:EP0979823B1
    公开(公告)日:2006-03-29
  • US6849647B1
    申请人:——
    公开号:US6849647B1
    公开(公告)日:2005-02-01
  • US7393866B2
    申请人:——
    公开号:US7393866B2
    公开(公告)日:2008-07-01
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑-d4 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺 苯并噻唑-2-基(对甲苯基)甲醇 苯并噻唑-2-乙酸甲酯 苯并噻唑-2-乙腈 苯并噻唑-2(3H)-酮N2-[1-(吡啶-4-基)乙亚基]腙 苯并噻唑-2 - 丙基 苯并噻唑,6-(3-乙基-2-三氮烯基)-2-甲基-(8CI)